Jim Cramer expressed disappointment in Eli Lilly’s handling of a drug trial, urging them to communicate better. The company develops pharmaceuticals for various health needs, including diabetes and cancer. While LLY shows investment potential, AI stocks may offer greater upside. For more information on AI stocks, check out a free report online.

Read more at Yahoo Finance: Jim Cramer Says He is “Very Upset” With Eli Lilly